<< Back
Vitae Pharmaceuticals’ President and CEO Jeffrey Hatfield Recognized by the Pennsylvania Life Sciences Awards Program as a CEO of the Year

Fort Washington, PA, September 29, 2010 --Vitae Pharmaceuticals announced today that the inaugural, Pennsylvania-area LifeSciences Awards program has recognized President and CEO Jeffrey Hatfield as a Life Sciences CEO of the Year. Vitae is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets with significant unmet medical needs, including chronic kidney disease, diabetes, Alzheimer's disease and atherosclerosis.

An independent panel of judges from leading universities in the state selected the winners of the Life Sciences Awards, which serve to recognize the region’s medical miracle makers for their innovative approaches to improving the delivery of health care. The Life Sciences Awards are presented by The Philadelphia Business Journal and have been launched in sponsorship with the University of the Sciences and partners Pennsylvania Bio and Safeguard Scientifics. “I am honored to be among such as a select group of CEOs recognized by the Life Sciences Awards program,” stated Mr. Hatfield. “The Pennsylvania region is distinguished as a leading center for innovation, and Vitae is pleased to be a part of this thriving life sciences community.”

About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets, including chronic kidney disease, diabetes, Alzheimer’s disease and atherosclerosis. Vitae’s lead compound, VTP-27999, is a wholly owned, novel, potent and selective renin inhibitor offering the potential for superior renal protection in patients suffering from chronic kidney disease. The compound is advancing through Phase I clinical trials and results will be presented by early 2011.

Vitae is an expert in structure-based drug discovery and combines a proprietary technical platform with the experience and insight of world class scientists to advance best-in-class compounds for high value, hard-to-drug targets. Vitae’s proprietary, discovery platform has clear advantages in creating and analyzing novel drug candidates that meet pre-defined physicochemical characteristics. The accuracy and speed of this system has enabled Vitae to solve challenging targets in multiple therapeutic areas -- discovering and advancing attractive compounds in a rapid and highly capital efficient manner. Vitae Pharmaceuticals is financed by leading corporate and venture capital investors; its last venture round was in 2004. Vitae’s 45 scientists are located in Fort Washington, Pennsylvania. For additional information, please visit the company’s website, www.vitaepharma.com.

Burns McClellan on behalf of Vitae
Justin Jackson, MichelleSzwarcberg (media),

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Vitae Pharmaceuticals Inc's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.